4.93  0.05 (1.02%)		06-15 16:00
Open: 5.01 High: 5.1299 Volume: 240,489		Pre. Close: 4.88 Low: 4.78 Market Cap: 28(M)

Short term
Mid term
Targets	6-month :	6.19	1-year :	7.23
Resists	First :	5.3	Second :	6.19
Pivot price	4.53
Supports	First :	3.97	Second :	3.16
MAs	MA(5) :	4.9	MA(20) :	4.53
	MA(100) :	5.86	MA(250) :	4.85
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	89.7	D(3) :	87.2
RSI	RSI(14): 53.2
52-week	High :	11.89	Low :	3.16

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CING ] has closed below upper band by 22.7%. Bollinger Bands are 29.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.14 - 5.16	5.16 - 5.17
Low:	4.73 - 4.75	4.75 - 4.77
Close:	4.96 - 5	5 - 5.03

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Wed, 10 Jun 2026
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits

Thu, 04 Jun 2026
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26 - Yahoo Finance

Tue, 02 Jun 2026
Cingulate Receives Complete Response Letter from FDA for CTx-1301 - GlobeNewswire

Tue, 02 Jun 2026
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues - Reuters

Tue, 02 Jun 2026
Cingulate ADHD drug faces FDA data request, no safety concerns cited - Stock Titan

Sun, 31 May 2026
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	13 (M)
Shares Float	13 (M)
Held by Insiders	30.5 (%)
Held by Institutions	8.8 (%)
Shares Short	1,960 (K)
Shares Short P.Month	1,500 (K)

EPS	-4.33
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.58
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-69.7 %
Return on Equity (ttm)	-225.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.73
Sales Per Share	0
EBITDA (p.s.)	-1.76
Qtrly Earnings Growth	0 %
Operating Cash Flow	-20 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-1.16
PEG Ratio	0
Price to Book value	3.16
Price to Sales	0
Price to Cash Flow	-3.45

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.